PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.10
Ask: 3.40
Change: -0.10 (-2.99%)
Spread: 0.30 (9.677%)
Open: 3.35
High: 3.35
Low: 3.25
Prev. Close: 3.35
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue

Wed, 27th Mar 2024 11:02

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Norman Broadbent PLC, up 13% at 8.75 pence, 12-month range 4.50p-9.32p. The London-based recruitment firm swings to a pretax profit in 2023 of GBP309,000 from a loss of GBP338,000 in 2022. This tracks revenue rising 41% to GBP12.3 million from GBP8.7 million, partially offset by operating expenses rising 34%to GBP10.2 million from GBP7.6 million and cost of sales rising 21% to GBP1.7 million from GBP1.4 million. Chief Executive Officer Kevin Davidson comments: "We have taken the opportunity to invest further in the Company, hiring exceptional people and building our platform to take advantage of the market rebound when it comes. Our ambition remains steadfast and we will continue to pursue our aggressive growth strategy, whilst remaining profitable and cash positive, both organically and potentially through synergistic M&A opportunities...Supported by our considerable brand strength and market leading processes and technologies, we are well-positioned for continued success."

----------

Allergy Therapeutics PLC, up 11% at 3p, 12-month range 0.37p-3.20p. In the six months that ended December 31, the Sussex, England-based biotechnology company reports pretax loss widening to GBP14.9 million from GBP8.2 million a year earlier. Revenue falls 16% to GBP33.6 million from GBP39.9 million, while financial expenses soar to GBP3.2 million from GBP398,000. Chief Executive Officer Manuel Llobet comments: "2023 has been an important year, marked by a highly focused approach to our business priorities, and a steadfast commitment to our Grass and Peanut allergy research & development programmes. We have navigated the challenges of last year, resulting in more streamlined operations and improved cost-effectiveness. This progress starts to pave the way towards a return to growth." Allergy Therapeutics also notes that its lenders have agreed that a further GBP15 million may be drawn from the existing GBP40 million amended loan facility from the second quarter of calendar 2024, with the first GBP7.5 million having already been drawn down. It says this extends its cash runway into the first quarter of its financial 2025. The lenders are major shareholders SkyGem Acquisition, which is an affiliate ZQ Capital Management, alongside Southern Fox Investments.

----------

AIM - LOSERS

----------

Infrastructure India PLC, down 80% at 0.10p, 12-month range 0.10p-1.27p. In the six months that ended September 30, the infrastructure fund investing directly into assets in India reports pretax loss narrowing to GBP31.5 million from GBP62.2 million a year earlier, largely driven by foreign exchange loss narrowing to GBP3.7 million from GBP40.8 million. Shares restarted trading on Wednesday after publishing its annual results for the financial year ended March 31 on Tuesday. During this period, pretax loss widened to GBP59.2 million from GBP48.4 million a year earlier. The company says: "The group has prepared the interim results on a basis other than going concern due to the uncertainty in relation to the timing of potential transactions, ultimate receipt of sale proceeds and the specifics of any deferred consideration. This basis was considered the most appropriate method for the reporting period."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
7 Dec 2015 07:54

Allergy Therapeutics Begins US Phase II Study Of Grass Allergy Vaccine

Read more
30 Nov 2015 09:25

Allergy Therapeutics Completes Patient Enrolment For Birch Study

Read more
17 Nov 2015 14:36

Allergy Therapeutics raises £12m to develop peanut and dust mite treatments

(ShareCast News) - Shares in Allergy Therapeutics fell as, despite a strong trading update, the company launched a £12m discounted fundraising to speed development of treatments for peanut allergy and house dust mites allergies. The AIM-listed company completes the institutional placing by mid-after

Read more
17 Nov 2015 13:03

UPDATE: Allergy Therapeutics Raises GBP11.5 Million To Fund Growth (ALLISS)

Read more
17 Nov 2015 10:14

Allergy Therapeutics To Raise GBP12 Million To Fund Growth (ALLISS)

Read more
16 Nov 2015 16:37

AGM, EGM Calendar - Week Ahead

Read more
4 Nov 2015 10:43

Allergy Therapeutics To Present Adjuvant Data At Spain Conference

Read more
13 Oct 2015 08:43

BROKER RATINGS SUMMARY: Citi Cuts AB Foods As UBS Raises Smiths Group

Read more
21 Sep 2015 08:11

Allergy Therapeutics Says Outlook "Very Positive" As Profit Falls

Read more
14 Sep 2015 14:58

Earnings, Trading Statements Calendar - Week Ahead

Read more
1 Sep 2015 08:35

Allergy Therapeutics Enrols First Patient For Birch Drug Study

Read more
10 Aug 2015 07:23

Allergy Therapeutics Says Paper Published In World Allergy Journal

Read more
27 Jul 2015 16:58

Allergy Technologies' chief executive buys 50,000 shares

(ShareCast News) - The chief executive of Allergy Therapeutics bought new shares in the company few days after releasing a positive trading update. Manuel Llobet purchased 50,000 shares for an individual price of 24.45p, spending a total of £12,225. After the transaction, Llobet holds 3.175m shares

Read more
27 Jul 2015 16:24

DIRECTOR DEALINGS SUMMARY: New MySale Chairman Buys 60,000 Shares

Read more
27 Jul 2015 11:37

DIRECTOR DEALINGS: Allergy Therapeutics CEO Buys 50,000 Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.